查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1493385

美国寡核苷酸合成市场规模、份额、趋势分析报告：按产品/服务、按应用、按最终用途、细分市场预测，2024-2030

U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By Product & Service (Oligonucleotides, Equipment/Synthesizer), By Application (PCR Primers, Sequencing), By End-use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国寡核苷酸合成市场成长与趋势：

根据Grand View Research, Inc.的最新报告，预计到2030年美国寡核苷酸合成市场规模将达到30.9亿美元，预计2024年至2030年复合年增长率为12.80%。

由于分子诊断需求的增加、新应用的出现以及心血管疾病、视网膜疾病和癌症等难治性适应症的新机会，预计寡核苷酸治疗药物的需求将在预测期内增加。酸合成的需求。

COVID-19大流行对美国寡核苷酸合成产业产生了积极影响。然而，在大流行期间，随着製药公司和医疗保健专业人员发现了寡核苷酸的更有效用途，并专注于其应用以遏制COVID-19 的传播，对寡核苷酸合成的需求随之增加。例如，创新基因组研究所在2020年表示，正在开发雾化、锁定、核酸修饰的反义寡核苷酸，可以透过呼吸或雾化吸入来治疗COVID-19感染。这些进步引起了医疗保健提供者的兴趣。因此，疫情对美国市场产生了正面影响。

此外，该公司正在增加投资以开发基于寡核苷酸的疗法。例如，2023年10月，GSK plc和Arrowhead Pharmaceuticals与强生公司旗下杨森製药公司（Janssen）达成协议，获得JNJ-3989的全球独家开发和商业化权利，并宣布双方已签署协议。葛兰素史克。杨森最初于 2018 年从 Arrowhead 引入了 JNJ-3989（以前称为 ARO-HBV）。成熟製药公司的类似倡议预计将在预测期内推动市场成长。

然而，儘管寡核苷酸合成是一个有前景的应用，但将其投入实用化仍有挑战和问题。从合成中获得高产率的最重要参数之一是监测偶联效率。即使平均耦合中的小故障率也会对长序列产生巨大影响。平均耦合失效的微小变化会导致巨大的净效应。因此，即时监控每个自订化合成对于每个平台都至关重要，预计会在一定程度上阻碍市场成长。

美国寡核苷酸合成市场报告亮点

  • 2023年销售份额为37.34%，服务在产品和服务领域占据主导地位。这是由于对专业服务的需求不断增长。随着基因组研究和治疗应用变得更加复杂，研究人员和公司越来越多地外包寡核苷酸序列的合成、精製和客製化。另一方面，预计寡核苷酸在预测期内将以最快的速度成长。
  • 在应用领域，PCR引子在2023年占据最大的市场占有率。专有的 PCR 引子使实验室能够检测病原体中的微量 DNA 或 RNA，有助于识别包括病毒、细菌和寄生虫感染在内的感染疾病。同时，定序预计在预测期内将以最快的速度成长。
  • 从最终用途来看，学术和研究机构在该领域占据主导地位，2023 年收益占有率最高，达 43.16%。这是由于学术研究机构进行的临床研究数量的增加以及研究活动经费的增加。另一方面，製药和生物技术公司预计在预测期内将以最快的复合年增长率成长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章美国寡核苷酸合成市场：产品与服务的商业分析

  • 细分仪表板
  • 美国寡核苷酸合成市场产品与服务波动分析
  • 2018-2030年美国寡核苷酸合成市场规模与趋势分析（依产品与服务）
  • 寡核苷酸
  • 设备/合成设备
  • 试剂
  • 服务
    • DNA
    • RNA

第五章美国寡核苷酸合成市场：应用商业分析

  • 细分仪表板
  • 美国寡核苷酸合成市场应用变化分析
  • 2018-2030年美国寡核苷酸合成市场规模及趋势分析（依应用）
  • PCR引子
  • PCR 检测和麵板
  • 定序
  • DNA微阵列
  • 萤光原位杂合反应（FISH）
  • 反义寡核苷酸
  • 其他用途

第六章美国寡核苷酸合成市场：最终用途业务分析

  • 细分仪表板
  • 美国寡核苷酸合成市场的最终用途变化分析
  • 2018-2030年美国寡核苷酸合成市场规模与趋势分析（依最终用途）
  • 学术研究所
  • 诊断实验室
  • 製药和生物技术公司

第七章 竞争状况

  • 参与企业
  • 策略规划
  • 2023 年企业市场分析
  • 参与企业概况
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Danaher Corporation
    • Dharmacon Inc.
    • Agilent Technologies
    • Bio-synthesis
    • LGC Biosearch Technologies
    • Twist Bioscience
    • TriLink BioTechnologies
    • Genscript
Product Code: GVR-4-68040-290-5

U.S. Oligonucleotide Synthesis Market Growth & Trends:

The U.S. oligonucleotide synthesis market size is anticipated to reach USD 3.09 billion by 2030 and is projected to grow at a CAGR of 12.80% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising demand for molecular diagnostics, emerging novel applications, and growing demand for oligonucleotide therapeutics owing to the emerging potential for incurable indications such as cardiovascular diseases, retinal disorders, and cancer are anticipated to increase the demand for oligonucleotide synthesis over the forecast period.

The COVID-19 pandemic has had a positive impact on the U.S. oligonucleotide synthesis industry. During the pandemic, however, the demand for oligonucleotide synthesis grew as pharmaceutical companies and healthcare professionals focused on identifying more efficient usage of oligonucleotides and their application to limit the spread of COVID-19. For instance, the Innovative Genomic Institute stated in 2020 that it was developing an aerosolized, locked nucleic acid modifying antisense oligonucleotide that can be breathed or nebulized to treat COVID-19 infection. Such advances piqued the interest of healthcare providers. Hence, the pandemic has had a favorable impact on the U.S. market.

Moreover, companies have increased investments to develop oligonucleotide-based therapeutics. For instance, in October 2023, GSK plc and Arrowhead Pharmaceuticals announced a contract with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to assign GSK the exclusive worldwide rights to develop and commercialize JNJ-3989. Janssen initially in-licensed JNJ-3989 (previously ARO-HBV) from Arrowhead in 2018. Similar initiatives by well-established pharmaceutical companies are anticipated to drive market growth over the forecast period.

However, oligonucleotide synthesis encounters challenges and problems in practical applications, even with high-potential applications. One of the most critical parameters to get a high yield from synthesis is monitoring its coupling efficiency. Even the slightest rate of failure in average coupling causes dramatic effects in long sequences. A minor change in average coupling failure leads to a substantial net effect. Thus, real-time monitoring of each custom synthesis becomes essential for every platform and, thereby, is anticipated to hamper the growth of the market to a certain extent.

U.S. Oligonucleotide Synthesis Market Report Highlights:

  • Services dominated the product & service segment with the largest revenue share of 37.34% in 2023. This is attributed to the growing demand for specialized services. As the complexity of genomic research and therapeutic applications increases, researchers & companies are turning to outsourcing for the synthesis, purification, and customization of oligonucleotide sequences. On the other hand, oligonucleotide are expected to grow at the fastest rate over the forecast period.
  • The PCR primers held the largest market share in 2023 for the application segment. Unique PCR primer allows labs to detect tiny quantities of DNA or RNA from pathogens, assisting in the identification of infectious diseases, including viral, bacterial, and parasitic infections. On the other hand, sequencing is expected to grow at the fastest rate over the forecast period.
  • Based on end use, academic research institutes dominated the segment with the largest revenue share of 43.16% in 2023. This is attributed to the increasing number of clinical studies, which are being conducted in academic institutes and the growing funding for research activities. On the other hand, pharmaceutical & biotechnology companies are anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Application
    • 1.2.3. End-use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Strong pipeline of oligonucleotide therapeutics in clinical trials
      • 3.2.1.2. High R&D spending of pharmaceutical & biotechnology companies
      • 3.2.1.3. Technological advancements in gene editing technologies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Need for advanced oligo synthesis solutions
      • 3.2.2.2. High cost associated with genomics research
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Oligonucleotide Synthesis Market: Product & Service Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Oligonucleotide Synthesis Market Product & Service Movement Analysis
  • 4.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Product & Service, 2018 to 2030 (USD Million)
  • 4.4. Oligonucleotides
    • 4.4.1. Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1. DNA
      • 4.4.1.1.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.2. Column-based
      • 4.4.1.1.2.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.1.3. Array-based
      • 4.4.1.1.3.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2. RNA
      • 4.4.1.2.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2. By Technology
      • 4.4.1.2.2.1. Column-based
      • 4.4.1.2.2.1.1. Column-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.2.2. Array-based
      • 4.4.1.2.2.2.1. Array-based market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3. By Type
      • 4.4.1.2.3.1. Short RNA Oligos (<65 nt)
      • 4.4.1.2.3.1.1. Short RNA oligos (<65nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.2. Long RNA Oligos (>65 nt)
      • 4.4.1.2.3.2.1. Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.4.1.2.3.3. CRISPR (sgRNA)
      • 4.4.1.2.3.3.1. CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million
  • 4.5. Equipment/Synthesizer
    • 4.5.1. Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.6. Reagents
    • 4.6.1. Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • 4.7. Services
    • 4.7.1. Services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.2. DNA
      • 4.7.2.1. DNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2. Custom Oligo Synthesis Services
      • 4.7.2.2.1. 25 nmol
      • 4.7.2.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.2. 50 nmol
      • 4.7.2.2.2.1. 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.3. 200 nmol
      • 4.7.2.2.3.1. 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.4. 1000 nmol
      • 4.7.2.2.4.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.2.5. 10000 nmol
      • 4.7.2.2.5.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.3. Modification Services
      • 4.7.2.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.2.4. Purification Services
      • 4.7.2.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.7.3. RNA
      • 4.7.3.1. RNA market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2. Custom Oligo Synthesis Services
      • 4.7.3.2.1. 25 nmol
      • 4.7.3.2.1.1. 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.2. 100 nmol
      • 4.7.3.2.2.1. 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.3. 1000 nmol
      • 4.7.3.2.3.1. 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.2.4. 10000 nmol
      • 4.7.3.2.4.1. 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.3. Modification Services
      • 4.7.3.3.1. Modification services market estimates and forecast, 2018 - 2030 (USD Million)
      • 4.7.3.4. Purification Services
      • 4.7.3.4.1. Purification services market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Oligonucleotide Synthesis Market: Application Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Oligonucleotide Synthesis Market Application Movement Analysis
  • 5.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. PCR Primer
    • 5.4.1. PCR primer market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. PCR Assay & Panel
    • 5.5.1. PCR assay & panel market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Sequencing
    • 5.6.1. Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. DNA Microarrays
    • 5.7.1. DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.8. Fluorescence In Situ Hybridization (FISH)
    • 5.8.1. Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.9. Antisense Oligonucleotides
    • 5.9.1. Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.10. Other Applications
    • 5.10.1. Other applications market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Oligonucleotide Synthesis Market: End-use Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Oligonucleotide Synthesis Market End-use Movement Analysis
  • 6.3. U.S. Oligonucleotide Synthesis Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 6.4. Academic Research Institutes
    • 6.4.1. Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5. Diagnostic Laboratories
    • 6.5.1. Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6. Pharmaceutical & Biotechnology Companies
    • 6.6.1. Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2023
  • 7.4. Participant's Overview
    • 7.4.1. Thermo Fisher Scientific, Inc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product & service benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Merck KGaA
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product & service benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Danaher Corporation
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product & service benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Dharmacon Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product & service benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Agilent Technologies
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product & service benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Bio-synthesis
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product & service benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. LGC Biosearch Technologies
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product & service benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Twist Bioscience
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product & service benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. TriLink BioTechnologies
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product & service benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Genscript
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product & service benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. oligonucleotide synthesis market, by product & service, 2018 - 2030 (USD Million)
  • Table 4 U.S. oligonucleotide synthesis market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. oligonucleotide synthesis market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 Participant's overview
  • Table 7 Financial performance
  • Table 8 Key companies undergoing expansions
  • Table 9 Key companies undergoing acquisitions
  • Table 10 Key companies undergoing collaborations
  • Table 11 Key companies launching new products/services
  • Table 12 Key companies undertaking other strategies

List of Figures

  • Fig. 1 U.S. oligonucleotide synthesis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. oligonucleotide synthesis market driver analysis
  • Fig. 14 U.S. oligonucleotide synthesis market restraint analysis
  • Fig. 15 U.S. oligonucleotide synthesis market: Porter's analysis
  • Fig. 16 U.S. oligonucleotide synthesis market: Product & service outlook key takeaways
  • Fig. 17 U.S. oligonucleotide synthesis market: Product & service movement analysis
  • Fig. 18 Oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Column-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Array-based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Short RNA oligos (<65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Long RNA oligos (>65 nt) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 CRISPR (sgRNA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Equipment/synthesizer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Reagents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 DNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 50 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 200 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 RNA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Custom oligo synthesis services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 25 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 100 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 1000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 10000 nmol market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Modification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Purification services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. oligonucleotide synthesis market: Application movement analysis
  • Fig. 49 U.S. oligonucleotide synthesis market: Application outlook and key takeaways
  • Fig. 50 PCR primers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 PCR assays & panels market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Sequencing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 DNA microarrays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Fluorescence in situ hybridization (FISH) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Antisense oligonucleotides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Other applications market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. oligonucleotide synthesis market End-use outlook key takeaways
  • Fig. 58 U.S. oligonucleotide synthesis market: End-use movement analysis
  • Fig. 59 Academic research institutes market estimates and forecast, 2018 - 2030 (USD Million))
  • Fig. 60 Diagnostic laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Pharmaceutical & biotechnology companies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Key company categorization
  • Fig. 63 Company market positioning
  • Fig. 64 Market participant categorization
  • Fig. 65 Strategy framework